Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Fresenius Medical Care AG & Co. KGAA (“Fresenius” or the “Company”) (NYSE: FMS) concerning possible violations of federal securities laws.

If you purchased shares of Fresenius and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

Fresenius is a kidney dialysis company that provides dialysis treatment and similar dialysis care services, and other health services.

On January 7, 2017, Fresenius revealed that it received subpoenas from federal prosecutors related to the Company’s interactions with the American Kidney Fund, a national charity offering financial aid for kidney dialysis patients.

When this information was released to the public, Fresenius stock dropped as much as 6.70% on January 9, 2017, causing investors harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.